###### Abstract  
Bacterial vagnosis (BV) is the most common vaginal infection globally, with a high recurrent rate after antibiotic treatment. Probiotics consumption is known to improve BV with different efficacy among species or strains. After in vitro selection of _Lactobacillus_ strains with growth inhibition and preventing adhesion to HeLa cervical epithelial cells, a randomized and double-blinded trial of two _Lactobacillus_ formula, namely, VGA-1 and VGA-2, in BV patients with Nugent scores of 4-10 was conducted. Among 37 subjects who completed the trial, we observed significantly decreased Nugent scores in both VGA-1 (\(n=18\)) and VGA-2 (\(n=19\)) consumption groups. VGA-1 consumption significantly improved vaginal discharge odor/color and itching at both 2-week and 4-week-consumption, but those only observed after a 4-week-consumption in the VGA-2 group. We also observed a tendency to reduce recurrent rates among enrolled participants after VGA-1 or VGA-2 consumption. The improvement effect of VGA-1/VGA-2 was associated with the significant reduction of interleukin-6 expression after 4-week-consumption and the restoration of normal vaginal microflora by quantitative polymerase chain reaction analysis. In conclusion, VGA-1 or VGA-2 displayed beneficial effects in BV patients, but the VGA-1 formula showed a better efficacy, potentially used for BV intervention. b 2021 11 902. 11. 11. 11. 11. 11. 11. 11. 11. 11. 1. 11. 1.  
premature birth [6], and low-birth-weight babies [7]. The change of vaginal microflora is a characteristic in BV [8]. _Lactobacillus_, including _L. crispatus_, _L. gasseri_, _L. niers_, and _L. jensenii_, are the most abundant normal flora in vaginas with the ability to secrete lactic acid to maintain the vaginal acidic environment, thus inhibiting the growth of pathogenic bacteria [9]. In addition, the productions of hydrogen peroxide (H\({}_{2}\)O\({}_{2}\)) and antimicrobial peptides by _Lactobacillus_ are considered mechanisms in the suppression of pathogenic bacteria in vaginas [10]. The depletion of _Lactobacillus_ together with the outgrowth of predominantly anaerobic microorganisms including _Gardnerella vaginalis_, _Prevotella_, _Peptostreptococcus_, and _Bacteroides_ spp. are characteristics of BV [11]. The aerobic pathogenic bacteria in BV include _Escherichia coli_, _Staphylococcus aureus_, and group B _Streptococcus_[12]. Oral or intravascular administration of antibiotics, such as metronidazolezo or clindamycin treatment, is the current medication for BV with a high cure rate; however, 20% to 75% of patients experience recurrence within 3 months [13]. This condition indicates the need to develop new agents for BV medication. Given the unbalanced vaginal microflora in BV, probiotic consumption is used to ameliorate this disease through reconstruction of the vaginal microbial environment. [PERSON] et al. proposed a criteria for the selection of probiotics used for BV intervention, including the adherence to vaginal epithelial cells, exclusion or reduction of the adherence of pathogenic bacteria, or persistent replication and production of antagonist substances such as lactic acid or H\({}_{2}\)O\({}_{2}\)[14]. [PERSON] et al. conducted a randomized, double-blind, placebo-controlled trial of a probiotics formula consisting of _L. rhamns_ GR-1 and _L. reuteri_ RC-14 on BV for 60 days [15]. The participants exhibited a significantly increased percentage of restoration of normal vaginal microflora under microscopy examination [15]. Another BV trial of GR-1/RC-14 oral consumption for 28 days demonstrated a significantly high percentage of participants with normal vaginal microbiota by the Gram-stain Nugent score in the probiotic group [16]. In a meta-analysis of 10 blinded randomized controlled studies by [PERSON] et al., the decreased Nugent score was found in subjects with probiotics-only therapy, but were not significant in those with probiotics-antibiotics combination therapy at a 30-day-consumption protocol [17].